| Literature DB >> 32661735 |
Alexander Humberg1,2, Ingmar Fortmann1, Bastian Siller1, Matthias Volkmar Kopp1,3, Egbert Herting1, Wolfgang Göpel1, Christoph Härtel4,5.
Abstract
Almost half of all preterm births are caused or triggered by an inflammatory process at the feto-maternal interface resulting in preterm labor or rupture of membranes with or without chorioamnionitis ("first inflammatory hit"). Preterm babies have highly vulnerable body surfaces and immature organ systems. They are postnatally confronted with a drastically altered antigen exposure including hospital-specific microbes, artificial devices, drugs, nutritional antigens, and hypoxia or hyperoxia ("second inflammatory hit"). This is of particular importance to extremely preterm infants born before 28 weeks, as they have not experienced important "third-trimester" adaptation processes to tolerate maternal and self-antigens. Instead of a balanced adaptation to extrauterine life, the delicate co-regulation between immune defense mechanisms and immunosuppression (tolerance) to allow microbiome establishment is therefore often disturbed. Hence, preterm infants are predisposed to sepsis but also to several injurious conditions that can contribute to the onset or perpetuation of sustained inflammation (SI). This is a continuing challenge to clinicians involved in the care of preterm infants, as SI is regarded as a crucial mediator for mortality and the development of morbidities in preterm infants. This review will outline the (i) role of inflammation for short-term consequences of preterm birth and (ii) the effect of SI on organ development and long-term outcome.Entities:
Keywords: Chronic pulmonary insufficiency of prematurity; Microbiome; Neurocognitive outcome; Preterm infants; Sepsis; Sustained inflammation
Mesh:
Year: 2020 PMID: 32661735 PMCID: PMC7508934 DOI: 10.1007/s00281-020-00803-2
Source DB: PubMed Journal: Semin Immunopathol ISSN: 1863-2297 Impact factor: 9.623
Fig. 1Survival rates of preterm infants born at 24 weeks of gestation in different high-income countries [1–4]; GNN German Neonatal Network
Incidences of major short-term complications of preterm birth
| Outcome | EPI < 28 weeks | VPI 28–32 weeks | MPI/LPI 33–< 37 weeks | References |
|---|---|---|---|---|
| Intracerebral hemorrhage | ||||
| All | 15–25% | 1–4% | 1–2% | [ |
| Grade III–IV (Papile) | 3–6% | 1–2% | < 1% | |
| PVL | 2–8% | 1–6% | ? | |
| Sepsis | ||||
| Clinical | 25–60% | 10–30% | 5–9% | [ |
| Blood culture confirmed | 15–50% | 2–6% | 1–3% | [ |
| EOS | 1–1.5% | 0.1–0.3% | 0.1–0.2% | [ |
| LOS | 15–50% | 1.5–6% | 1–3% | [ |
| NEC requiring surgery | 4–10% | 0.5–3% | < 1% | [ |
| SIP requiring surgery | 3–8% | < 1% | < 1% | [ |
| Pneumothorax | 4–7% | 1–4% | 1–2% | [ |
| BPD | 15–50% | 5–25% | ? | [ |
| ROP | 2–5% | 1–3% | ? | [ |
| Death in hospital | 10–20% | 2–5% | 1% | [ |
PVL periventricular leukomalacia, EOS early-onset sepsis (≤ 72 h of age), LOS late-onset sepsis (> 72 h of age), NEC necrotizing enterocolitis, SIP spontaneous intestinal perforation, ROP retinopathy of prematurity, BPD bronchopulmonary dysplasia
Fig. 2Complex risk profile of preterm infants for sustained inflammation and long-term vulnerability. This simplified model depicts that preterm infants are at risk for sustained inflammation by the virtue of their immaturity and several environmental exposures (“inflammatory” hits). The neonatal immunity is primed by the feto-maternal interface and interacts with the yet unstable microbiome. A delicate balance is needed between tolerating microbiological colonization and adequate immune responses to invasive pathogens. The neonatal “inflammatory phenotype” may result from a disturbed immune-microbiome development. The acute inflammatory process often fails to be properly resolved after clinical recovery with the consequence of sustained inflammation. The cross talk between immunity and microbiota continues and is proposed to affect developmental trajectories and long-term outcomes. Longitudinal studies are needed to account for protective modulators and continued risks for dysregulatory influences. PPROM, preterm premature rupture of membranes
Fig. 3Ontogeny and potential impact of sustained inflammation on the development of the brain, lungs, kidneys, and immune system. IC, immune cells; PC, progenitor cells; NC, neutrophil cells; adapted from [45–52]
Targeting sustained inflammation to improve outcome in preterm infants: challenges and outcomes
| Challenge | Approach |
|---|---|
Inflammatory episodes (sepsis, NEC) remain predominant causes of mortality and long-term morbidity Large center-specific variations | Implementation of inflammation prevention bundles (hygiene, antibiotic stewardship programs, restrictive use of invasive measures, promotion of human milk feeding) Continuous establishment of quality improvement networks |
Understanding of underlying pathophysiological mechanisms Availability of animal models for preterm infants Limited opportunity to study tissue-specific aspects | Well-phenotyped large-scale longitudinal studies, systems biology approaches Mechanistic neonatal mouse or rhesus monkey models, in silico modeling Organoid models to investigate organ-specific mechanisms of SI |
| Disentangle the impact of prenatal and postnatal factors | Linking perinatal, neonatal datasets to follow-up data from cohort studies; target “neonatal window of opportunity” |
| Establishment of a physiological immune-microbiome adaptation despite postnatal intensive care | Basic research addressing long-term effects of perinatal exposures (e.g., antibiotics), postnatal biomarkers (e.g., S100 A8/9, Treg), and interventions (pre-/pro-/synbiotics; anti-inflammatory compounds; stem cells) Phase I–III clinical trials and randomized, placebo controlled trials with long-term follow-up |
| Lack of valid outcome measures of important organ functions (e.g., cognition, lung function) | Development of new tools for early short-term assessment; childhood follow-up with detailed determination of beneficial factors (human milk feeding, vaccinations) and harmful exposures (passive smoke, lack of participation) Define further “windows of opportunity” during infancy and childhood; study interventions to promote long-term health in controlled trials (e.g., music, sport, nutrition) |
| Targeted personalized therapies of preterm infants | Use of polygenic risk scores from adult cohorts for preterm infants and establishment of valuable trajectory-specific biomarkers (e.g., S100 A8/9) |